Similarities between the binding sites of SB-206553 at serotonin type 2 and alpha7 acetylcholine nicotinic receptors: Rationale for its polypharmacological profile

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Möller Acuña, Patricia ^a,b   Contreras Riquelme, J Sebastián ^a,c   Rojas Fuentes, Cecilia ^a   Nuñez Vivanco, Gabriel ^a   Alzate Morales, Jans ^a   Iturriaga Vásquez, Patricio ^d   Arias, Hugo R ^e   Reyes Parada, Miguel ^b,f  

^a UNIVERSIDAD DE TALCA   (Chile)

^b UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

^c Fundacion Ciencia para la Vida   (Chile)

^d UNIVERSIDAD DE LA FRONTERA   (Chile)

^e PLLC   (United States)

^f UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; ACETYLCHOLINE NICOTINIC RECEPTOR ALPHA7; CHOLINERGIC RECEPTOR; NICOTINIC RECEPTOR; PHOSPHOLIPASE A; PHOSPHOLIPASE C; SEROTONIN 2B RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; BUNGAROTOXIN RECEPTOR; INDOLE DERIVATIVE; ISOPROTEIN; PROTEIN BINDING; PYRIDINE DERIVATIVE; SEROTONIN 2 RECEPTOR; SEROTONIN ANTAGONIST;

ARTICLE; BILAYER MEMBRANE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG PROTEIN BINDING; DRUG STRUCTURE; LYMNAEA STAGNALIS; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PHYSICAL CHEMISTRY; POLYPHARMACOLOGY; SEQUENCE ALIGNMENT; SITE DIRECTED MUTAGENESIS; STEREOCHEMISTRY; STRUCTURAL HOMOLOGY; TORPEDO MARMORATA; AMINO ACID SEQUENCE; ANIMAL; BINDING COMPETITION; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BINDING, COMPETITIVE; HUMANS; INDOLES; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; PYRIDINES; RECEPTORS, SEROTONIN, 5-HT2; SEQUENCE HOMOLOGY, AMINO ACID; SEROTONIN ANTAGONISTS;

EID: 84941978806     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134444     Document Type: Article

References (57)

1. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682-690. doi: 10.1038/nchembio.118 PMID: 18936753
2. Schrattenholz A, Soski V. What does systems biology mean for drug development? Curr Med Chem. 2008;15:1520-1528. PMID: 18537627
3. Zhao S, Iyengar R. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol. 2012;52:505-521. doi: 10.1146/annurev-pharmtox-010611-134520 PMID: 22235860
4. Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;19:7874-7887.
5. Rognan D. Structure-based approaches to target fishing and ligand profiling. Mol Inf. 2010;29:176-187.
6. Kahraman A, Morris RJ, Laskowski RA, Thornton JM. Shape variation in protein binding pockets and their ligands. J Mol Biol. 2007;368:283-301. PMID: 17337005
7. Forbes IT, Ham P, Booth DH, Martin RT, Thompson M, Baxter GS, et al. 5-Methyl-1-(3-pyridylcarbamoyl) - 1, 2, 3, 5-tetrahydropyrrolo[2, 3-f]indole: a novel 5-HT2C/5-HT2B receptor antagonist with improved affinity, selectivity, and oral activity. J Med Chem. 1995;38:2524-2530. PMID: 7629791
8. Kennett GA, Wood MD, Bright F, Cilia J, Piper DC, Gager T, et al. In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties. Br J Pharmacol. 1996;117:427-434. PMID: 8821530
9. Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP. Novel actions of inverse agonists on 5-HT2C receptor systems. Mol Pharmacol. 1999;55:863-872. PMID: 10220565
10. Dunlop J, Lock T, Jow B, Sitzia F, Grauer S, Jow F, et al. Old and new pharmacology: positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor by the 5-hydroxytryptamine (2B/C) receptor antagonist SB-206553 (3, 5-dihydro-5-methyl-N-3-pyridinylbenzo[1, 2-b:4, 5-b']di pyrrole-1 (2H)-carboxamide. J Pharmacol Exp Ther. 2009;3:766-776.
11. Bockaert J, Claeysen S, Becamel C, Dumuis A, Marin P. Neuronal 5-HT metabotropic receptors: finetuning of their structure, signaling, and roles in synaptic modulation. Cell Tissue Res. 2006;326:553-572. PMID: 16896947
12. Wacker D, Wang C, Katritch V, Han GW, Huang XP, Vardy E, et al. Structural features for functional selectivity at serotonin receptors. Science. 2013;340:615-619. doi: 10.1126/science.1232808 PMID: 23519215
13. Papke RL. Merging old and new perspectives on nicotinic acetylcholine receptors. Biochem Pharmacol. 2014;89:1-11. doi: 10.1016/j.bcp. 2014.01.029 PMID: 24486571
14. Grutter T, Le Novere N, Changeux JP. Rational understanding of nicotinic receptors drug binding. Curr Top Med Chem. 2004;4:645-650. PMID: 14965300
15. Sali A, Blundell TL. Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993;234:779-815. PMID: 8254673
16. Celie PH, Van Rossum-Fikkert SE, Van Dijk WJ, Brejc K, Smit AB, Sixma TK. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron. 2004;41:907-914. PMID: 15046723
17. Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4 angstrom resolution. J Mol Biol. 2005;346:967-989. PMID: 15701510
18. Thompson JD, Higgins DG, Gibson TJ. Clustalw: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680. PMID: 7984417
19. Abagyan R, Totrov M, Kuznetsov D. ICM-A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. J Comput Chem. 1994;15:488-506.
20. Iturriaga-Vasquez P, Carbone A, Garcia-Beltran O, Livingstone PD, Biggin PC, Cassels BK, et al. Molecular determinants for competitive inhibition of alpha α4β2 nicotinic acetylcholine receptors. Mol Pharmacol. 2010;78:366-375. doi: 10.1124/mol.110.065490 PMID: 20547737
21. Faundez-Parraguez M, Farias-Rabelo N, Gonzalez-Gutierrez JP, Etcheverry-Berrios A, Alzate-Morales J, Adasme-Carreno F, et al. Neonicotinic analogues: selective antagonists for α4β2 nicotinic acetylcholine receptors. Bioorg Med Chem. 2013;21:2687-2694. doi: 10.1016/j.bmc.2013.03.024 PMID: 23561269
22. Pessoa-Mahana H, Gonzalez-Lira C, Fierro A, Zapata-Torres G, Pessoa-Mahana CD, Ortiz-Severin J, et al. Synthesis, docking and pharmacological evaluation of novel homo- and hetero-bis 3-piperazinylpropylindole derivatives at SERT and 5-HT1A receptor. Bioorg Med Chem. 2013;21:7604-7611. doi: 10.1016/j.bmc.2013.10.036 PMID: 24262884
23. Pessoa-Mahana H, Nunez CU, Araya-Maturana R, Barria CS, Zapata-Torres G, Pessoa-Mahana CD, et al. Synthesis, 5-hydroxytryptamine1A receptor affinity and docking studies of 3-[3-(4-aryl-1-piperazinyl) - propyl]-1H-indole derivatives. Chem Pharm Bull. 2012;60:632-638. PMID: 22689401
24. Melo F, Devos D, Depiereux E, Feytmans E. ANOLEA: a www server to assess protein structures. Proc Int Conf Intell Syst Mol Biol. 1997;5:187-190. PMID: 9322034
25. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26:283-291.
26. Schrodinger Suite 2009 Protein Preparation Wizard, Schrodinger, LLC, New York, NY, 2011.
27. Arias HR, Gu RX, Feuerbach D, Guo BB, Ye Y, Wei DQ. Novel positive allosteric modulators of the human α7 nicotinic acetylcholine receptor. Biochemistry. 2011;50:5263-5278. doi: 10.1021/bi102001m PMID: 21510634
28. Maestro-Desmond Interoperability Tools, version 3.0, Schrodinger, New York, NY, 2011.
29. National Center for Biotechnology Information. PubChem Compound Database; CID = 5163. Available: http://pubchem.ncbi.nlm.nih.gov/compound/5163. Accessed 1 Aug. 2014).
30. Stewart JJP. MOPAC: A general molecular orbital package. Quant Chem Prog Exch. 1990;10:86.
31. Morris M, Goodsell S, Halliday S, Huey R, Hart E, Belew K, et al. Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem. 1998;19:1639-1662.
32. Sotomayor-Zarate R, Quiroz G, Araya KA, Abarca J, Ibanez MR, Montecinos A, et al. 4-Methylthioamphetamine increases dopamine in the rat striatum and has rewarding effects in vivo. Basic Clin Pharmacol Toxicol. 2012;111:371-379. doi: 10.1111/j.1742-7843.2012.00926.x PMID: 22788961
33. Galeazzi R, Massaccesi L, Piva F, Principato G, Laudadio E. Insights into the influence of 5-HT2c aminoacidic variants with the inhibitory action of serotonin inverse agonists and antagonists. J Mol Model. 2014;20:2120. doi: 10.1007/s00894-014-2120-0 PMID: 24562856
34. Alzate-Morales JH, Vergara-Jaque A, Caballero J. Computational study on the interaction of N1 substituted pyrazole derivatives with B-Raf Kinase: an unusual water wire hydrogenbond network and novel interactions at the entrance of the active site. J Chem Inf Model. 2010;50:1101-1112. doi: 10.1021/ci100049h PMID: 20524689
35. Stone J, Cohen J, Sotomayor M, Villa E. VMD Molecular Graphics tutorial. 2007.
36. Yeturu K, Chandra N. PocketMatch: a new algorithm to compare binding sites in protein structures. BMC Bioinformatics. 2008;9:543. doi: 10.1186/1471-2105-9-543 PMID: 19091072
37. Fierro A, Montecinos A, Gomez-Molina C, Nunez G, Aldeco M, Edmondson DE, et al. Similarities between the binding sites of monoamine oxidase (MAO) from different species. Is zebrafish a useful model for the discovery of novel MAO inhibitors? In: Baptista GR, Editor. An integrated view of the molecular recognition and toxinology. From analytical procedures to biomedical applications.. Rijeka: InTech. Open Access Publisher; 2013. pp. 405.431.
38. Shulman-Peleg A, Shatsky M, Nussinov R, Wolfson HJ. MultiBind and MAPPIS: webservers for multiple alignment of protein 3D-binding sites and their interactions. Nucleic Acids Res. 2008;36(Web Server issue):W260-264. doi: 10.1093/nar/gkn185 PMID: 18467424
39. Wolfson HJ. Model-based object recognition by geometric hashing. In: Faugeras O, Editor. Computer vision ECCV90. Heidelberg: Springer, 1990. pp. 526.536.
40. Cordova-Sintjago T, Sakhuja R, Kondabolu K, Canal CE, Booth RG. Molecular determinants for ligand binding at serotonin 5-HT2A and 5-HT2C GPCRs: experimental affinity results analyzed by molecular modeling and ligand docking studies. Int J Quantum Chem. 2012;112:3807-3814. PMID: 23913978
41. Kim SK, Li Y, Abrol R, Heo J, Goddard WA III. Predicted structures and dynamics for agonists and antagonists bound to serotonin 5-HT2B and 5-HT2C receptors. J Chem Inf Model. 2011;51:420-433. doi: 10.1021/ci100375b PMID: 21299232
42. Lu C, Jin F, Li C, Li W, Liu G, Tang Y. Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods. J Mol Model. 2011;17:2513-2523. doi: 10.1007/s00894-010-0936-9 PMID: 21203788
43. Cordova-Sintjago TC, Villa N, Fang L, Booth RG. Aromatic interactions impact ligand binding and function at serotonin 5-HT2C G protein-coupled receptors: receptor homology modelling, ligand docking, and molecular dynamics results validated by experimental studies. Mol Phys. 2014;112:398-407. PMID: 24729635
44. Braden MR, Parrish JC, Naylor JC, Nichols DE. Molecular interaction of serotonin 5-HT2A receptor residues Phe339 (6.51) and Phe340 (6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol. 2006;70:1956-1964. PMID: 17000863
45. Roth BL, Shoham M, Choudhary MS, Khan N. Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine2A receptors. Mol Pharmacol. 1997;52:259-266. PMID: 9271348
46. Garcia-Sosa AT. Hydration properties of ligands and drugs in protein binding sites: tightly-bound, bridging water molecules and their effects and consequences on molecular design strategies. J Chem Inf Model. 2013;53:1388-1405. doi: 10.1021/ci3005786 PMID: 23662606
47. Bissantz C, Kuhn B, Stahl M. A medicinal chemist's guide to molecular interactions. J Med Chem. 2010;53:5061-5084. doi: 10.1021/jm100112j PMID: 20345171
48. Gill JK, Savolainen M, Young GT, Zwart R, Sher E, Millar NS. Agonist activation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA. 2011;108:5867-5872. doi: 10.1073/pnas.1017975108 PMID: 21436053
49. Collins T, Young GT, Millar NS. Competitive binding at a nicotinic receptor transmembrane site of two α7-selective positive allosteric modulators with differing effects on agonist-evoked desensitization. Neuropharmacology. 2011;61:1306-1313. doi: 10.1016/j.neuropharm.2011.07.035 PMID: 21820451
50. Castillo M, Mulet J, Bernal JA, Criado M, Sala F, Sala S. Improved gating of a chimeric alpha7-5HT3A receptor upon mutations at the M2-M3 extracellular loop. FEBS Lett. 2006;580:256-260. PMID: 16364316
51. Iorga B, Herlem D, Barre E, Guillou C. Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach. J Mol Model. 2006;12:366-372. PMID: 16372175
52. Young GT, Zwart R, Walker AS, Sher E, Millar NS. Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci USA. 2008;105:14686-14691. doi: 10. 1073/pnas.0804372105 PMID: 18791069
53. Bertrand D, Bertrand S, Cassar S, Gubbins E, Li J, Gopalakrishnan M. Positive allosteric modulation of the alpha7 nicotinic acetylcholine receptor: ligand interactions with distinct binding sites and evidence for a prominent role of the M2-M3 segment. Mol Pharmacol. 2008;74:1407-1416. doi: 10.1124/mol. 107.042820 PMID: 18678621
54. Spurny R, Debaveye S, Farinha A, Veys K, Vos AM, Gossas T, Atack J, Bertrand S, Bertrand D, Danielson UH, Tresadern G, Ulens C. Molecular blueprint of allosteric binding sites in a homologue of the agonistbinding domain of the α7 nicotinic acetylcholine receptor. Proc Natl Acad Sci U S A. 2015;112:E2543.2552. doi: 10.1073/pnas.1418289112 PMID: 25918415
55. Knight AR, Misra A, Quirk K, Benwell K, Revell D, Kennett G, et al. Pharmacological characterisation of the agonist radioligand binding site of 5-HT (2A), 5-HT (2B) and 5-HT (2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004;370:114-123. PMID: 15322733
56. Isberg V, Paine J, Leth-Petersen S, Kristensen JL, Gloriam DE. Structure-activity relationships of constrained phenylethylamine ligands for the serotonin 5-HT2 receptors. PLoS One 2013;8:e78515. doi: 10.1371/journal.pone.0078515 PMID: 24244317
57. Graves SM, Napier TC. SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamineseeking in rats. BMC Neurosci. 2012;13:65. doi: 10.1186/1471-2202-13-65 PMID: 22697313